CAS: 2410796-79-9; N-(2-(4,4-Difluoropiperidin-1-yl)-6-Methylpyrimidin-4-yl)-4-((2-Hydroxyethyl)Sulfonamido)-2-(6-Azaspiro[2.5]Octan-6-yl)Benzamide

英文名称N-(2-(4,4-Difluoropiperidin-1-yl)-6-Methylpyrimidin-4-yl)-4-((2-Hydroxyethyl)Sulfonamido)-2-(6-Azaspiro[2.5]Octan-6-yl)Benzamide
中文名称N-(2-(4,4-二氟哌啶-1-基)-6-甲基嘧啶-4-基)-4-((2-羟乙基)磺酰胺基)-2-(6-氮杂螺[2.5]辛烷-6-基)苯甲酰胺
IUPAC名称N-(2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl)-4-((2-hydroxyethyl)sulfonamido)-2-(6-azaspiro[2.5]octan-6-yl)benzamide
其它别名Benzamide, 2-(6-Azaspiro[2.5]Oct-6-yl)-N-[2-(4,4-Difluoro-1-Piperidinyl)-6-Methyl-4-Pyrimidinyl]-4-[[(2-Hydroxyethyl)Sulfonyl]Amino]-; Sovilnesib; N-(2-(4,4-Difluoropiperidin-1-yl)-6-Methylpyrimidin-4-yl)-4-((2-Hydroxyethyl)Sulfonamido)-2-(6-Azaspiro[2.5]Octan-6-yl)Benzamide
CAS编号2410796-79-9
MFCD编号:MFCD34578308
FDA UNII编号:OP393M4H32
分子式:C26H34F2N6O4S
分子量:564.66
产品CID: 1186308
产品分类Inhibitors/Agonists → Cell Cycle → Microtubule/Tubulin | Inhibitors/Agonists → Cell Cycle → Kinesin | Inhibitors/Agonists → Cell Cycle → Microtubule/Tubulin

相似结构搜索
InChIKey: KBDGEJDIHZDPHN-UHFFFAOYSA-N
KBDGEJDIHZDPHN-UHFFFAOYSA-N…
计算化学: 氢键受体数11.0氢键供体数3.0可旋转键数8.0

MSDS等安全信息

警示词Warning
危险描述H302-H315-H319-
防范说明P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P501-

合成工艺路线路线简述

海关参考信息

2912110000-甲醛
2912210000-苯甲醛
2924199090-其他无环酰胺
💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
详情请参考：📖 海关编码查询和海关进出口税则

专利信息

专利号:US-2025129050-A1
优先权日:2022-01-26
标题 :Synthesis of a kif18a inhibitor
发明人：CAILLE SEBASTIEN; GREENE DANIEL GERARD; CORBETT MICHAEL THOMAS; WEI CAROLYN
权利人:AMGEN INC
摘要:The present invention relates to improved preparation of a KIF18A inhibitor having the chemical structure Compound (1), or a salt thereof Compound (la); wherein HA is as defined herein; and key intermediates thereof, i.e., Compound (2a), Compound (3a), Compound (5) or a salt thereof, and Compound (6a) or a hydrate thereof, of the formulae: Compound (2a); Compound (3a); Compound (5) or a salt thereof; and Compound (6a) or a hydrate thereof, preferably Compound (6a-1). The present invention further relates to solid form of Compound (6a), preferably the crystalline hydrate form of Compound (6a-1).

专利号:JP-2025505892-A
优先权日:2022-01-26
标题 :Synthesis of KIF18A inhibitors

专利号:WO-2023146973-A1
优先权日:2022-01-26
标题 :Synthesis of a kif18a inhibitor

专利号:AU-2023211589-A1
优先权日:2022-01-26
标题:Synthesis of a kif18a inhibitor

专利号:TW-202342451-A
优先权日:2022-01-26
标题:Synthesis of a kif18a inhibitor

专利号:EP-4469437-A1
优先权日:2022-01-26
标题 :Synthesis of a kif18a inhibitor

其他信息查阅

安润医药科技(苏州)有限公司

网址: http://www.arromaxinc.com/
企业联系电话：13962124024👤
地址:苏州市工业园区华云路1号东坊产业园C区6号楼4楼

⚠️ 未注册 · 未认证企业

备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议，请通过页面底部联系方式告知我们，我们会尽快处理。

第 1 / 1 页

现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

实用工具

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

合成参考文献

参考文献:10.1093/oxfordjournals.jbchem.a131251
摘要:Nagano H, Kiuchi H, Abe Y, Shukuya R. Purification and properties of an alkaline ribonuclease from the hepatic cytosol fraction of bullfrog, Rana catesbeiana. J Biochem. 1976 Jul;80(1):19–26. doi: 10.1093/oxfordjournals.jbchem.a131251.